Avidity determinations for Haemophilus influenzae type b anti-polyribosylribitol phosphate antibodies

Clinical and Diagnostic Laboratory Immunology

Volumn 12, Issue 9, 2005, Pages 1029-1035

  Romero Steiner, Sandra ^a   Holder, Patricia F ^a   Gomez De Leon, Patricia ^b   Spear, Willie ^a,d   Hennessy, Thomas W ^c   Carlone, George M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; CHAOTROPIC AGENT; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G; POLYRIBOSYLRIBITOL PHOSPHATE ANTIBODY; REAGENT; THIOCYANATE SODIUM; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANALYTIC METHOD; ANTIBODY AFFINITY; ARTICLE; BINDING INTERFERENCE; CHILD; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; DILUTION; ELUTION; ELUTION ASSAY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNOLOGICAL PROCEDURES; MEASUREMENT; NORMAL HUMAN; PRIORITY JOURNAL; SERUM; SERUM DILUTION; VACCINATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; CHILD; CHILD, PRESCHOOL; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HUMANS; IMMUNOGLOBULIN G; INDICATOR DILUTION TECHNIQUES; MIDDLE AGED; POLYSACCHARIDES; THIOCYANATES;

EID: 24944515315     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.12.9.1029-1035.2005     Document Type: Article

References (24)

1. Amir, J., X. Liang, and D. M. Granoff. 1990. Variability in the functional activity of vaccines induced antibody to Haemophilus influenzae type b. Pediatr. Res. 27:358-364.
2. Antilla, M., J. Eskola, H. Åhman, and H. Käyhty. 1998. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J. Infect. Dis. 177:1614-1621.
3. Black, S. B., H. R. Shinefield, P. Ray, E. M. Lewis, B. Fireman, R. Hiatt, D. C. Madore, C. L. Johnson, J. G. Hackell, et al. 1993. Safety of combined oligosaccharide conjugate Haemophilus influenzae type b (HbOC) and whole cell diphtheria-tetanus toxoids-pertussis vaccine in infancy. Pediatr. Infect. Dis. J. 12:981-985.
4. Breukels, M. A., E. M. Jol-van der Zijde, M. J. D. vanTol, and G. T. Rijkers. 2002. Concentration and avidity of anti-Haemophilus influenzae type b (Hib) antibodies in serum samples obtained from patients for whom Hib vaccination failed. Clin. Infect. Dis. 34:191-197.
5. Bulkow, L. R., R. B. Wainwright, G. W. Letson, S. J. Chang, and J. I. Ward. 1993. Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr. Infect. Dis. J. 12:484-492.
6. Carlone, G. M., B. A. Perkins, T. Popovic, N. Rosenstein, and S, Romero-Steiner. 2002. Haemophilus influenzae type B, Neisseria meningitidis, Streptococcus pneumoniae, and Corynebacterium diphtheriae vaccines, p. 418-431. In N. R. Rose, R. G. Hamilton, and B. Detrick (ed.), Manual of clinical laboratory immunology, 6th ed. American Society for Microbiology, Washington, D.C.
7. Centers for Disease Control and Prevention. 1996. Progress toward elimination of Haemophilus influenzae type B disease among infants and children-United States, 1987-1995. Morb. Mortal. Wkly. Rep. 45:901-906.
8. Centers for Disease Control and Prevention. 2002. Summary of notifiable diseases-United States, 2000. Morb. Mortal. Wkly. Rep. 49:1-102.
9. Fernandez, J., S. Balter, J. Feris, E. Gómez, Z. Garib, P. L. Castellanos, J. Sanchez, S. Romero-Steiner, and O.S. Levine. 2000. Randomized trial of the immunogenicity of fractional-dose regimens of PRP-T Haemophilus influenzae type b conjugate vaccine. Am. J. Trop. Med. Hyg. 62:485-490.
10. Frasch, C. E. 1995. Haemophilus influenzae type b conjugate and combination vaccines. Clin. Immunother. 4:376-386.
11. Goldblatt, D., A. R. J. P. M. Pinto Vaz, and E. Miller. 1998. Antibody avidity as a surrogate marker of successful priming to Haemophilus influenzae type b conjugate vaccines following infant immunization. J. Infect. Dis. 177:1112-1115.
12. Gray, B. M., and D. R. Shaw. 1993. Artifacts with the thiocyanate elution method for estimating relative antibody avidity. J. Immunol. Methods 157: 269-271.
13. Harlow, E., and D. Lane. 1998. Using antibodies: a laboratory manual, 1st ed., p. 23-37. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
14. Hetherington, S. V., and A. F. Rutkowski. 1990. Antibody affinity in infants after immunization with conjugated capsular polysaccharide from Haemophilus influenzae type b. J. Infect. Dis. 162:1185-1188.
15. Madore, D., P. Anderson, B. D. Baxter, G. M. Carlone, K. M. Edwards, R. G. Hamilton, P. Holder, H. Käyhty, D. C. Phipps, C. C. A. Peeters, R. Schneerson, G. R. Siber, J. I. Ward, and C. E. Frasch. 1996. Intel-laboratory study evaluating quantitation of antibodies to Haemophilus influenzae type b polysaccharide by enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 3:84-88.
16. Madore, D.V., C.L. Johnson-Kraines, E. P. Rothstein, D. H. Smith, et al. 1999. Kinetics of antibody response to Haemophilus influenzae type b vaccines. Curr. Med. Res. Opin. 15:105-112.
17. Plikaytis, B., P. F. Holder, L. B. Pais, S. E. Maslanka, L. L. Gheesling, and G. M. Carlone. 1994. Determination of parallelism and non-parallelism in bioassay dilution curves. J. Clin. Microbiol. 32:2441-2447.
18. Pullen, G. R., M. G. Fitzgerald, and C. S. Hosking. 1986. Antibody avidity determination by ELISA using thiocyanate elution. J. Immunol. Methods 86:83-87.
19. Romero-Steiner, S., D. M. Musher, M. S. Cetron, L. B. Pais, J. E. Groover, A. E. Fiore, B. D. Plikaytis, and G. M. Carlone. 1999. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin. Infect. Dis. 29:281-288.
20. Romero-Steiner, S., J. Fernandez, C. Biltoft, M. E. Wohl, J. Feris, S. Balter, O. S. Levine, and G. M. Carlone. 2001. Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus conjugate). Clin. Diagn. Lab. Immunol. 8:1115-1119.
21. Romero-Steiner, S., W. Spear, N. Brown, P. Holder, T. Hennessy, P. Gomez de Leon, and G. M. Carlone. 2004. Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator. Clin. Diagn. Lab. Immunol. 11:89-93.
22. Schlesinger, Y., D. M. Granoff, and the Vaccine Study Group. 1992. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. JAMA 267:1489-1494.
23. Trotter, C., N. J. Andrews, E. B. Kaczmarski, E. Miller, and M. E. Ramsay. 2004. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364:365-367.
24. van Dam, G. J., A. F. M. Verheul, G. J. W. J. Zigterman, M. J. de Reuver, and H. Snippe. 1989. Estimation of the avidity of antibodies in polyclonal antisera against Streptococcus pneumoniae type 3 by inhibition ELISA. Mol. Immunol. 26:269-274.